New research shows a common weight loss medication may be effective in treating obesity in children as young as 6 years old.
Novo Nordisk shared results from a phase 3 clinical trial at an obesity medicine conference this week showing that its drug, Wegovy, reduced Body Mass Index by 10% or more among most children with obesity ages 6 through 11.
After 68 weeks, almost 40% of children taking semaglutide -- the active ingredient in Wegovy -- no longer had obesity.


Comments